Strategic Partners A/S (CPH:STRAP)
Denmark · Delayed Price · Currency is DKK 640.00
-5.00 (-0.78%)
Apr 21, 2026, 12:40 PM CET
Strategic Partners Revenue
In the year 2025, Strategic Partners had annual revenue of 309.00K DKK. Strategic Partners had revenue of 309.00K in the half year ending December 31, 2025.
Revenue
309.00K
Revenue Growth
n/a
P/S Ratio
87.07
Revenue / Employee
309.00K
Employees
1
Market Cap
26.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 309.06B |
| Coloplast | 27.89B |
| Genmab | 23.66B |
| Demant | 22.97B |
| Gubra | 2.64B |
| Scandinavian Medical Solutions | 245.44M |
| BioPorto | 40.29M |
| Monsenso | 8.91M |
Strategic Partners News
- 6 years ago - Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe - GlobeNewsWire
- 6 years ago - Orphazyme files final prospectus in connection with a global offering, consisting of initial public offering of American Despositary Shares in the United States and concurrent private placement of ordinary shares in Europe - GlobeNewsWire
- 6 years ago - Orphazyme publishes a prospectus regarding listing of 7,616,146 new ordinary shares on Nasdaq Copenhagen in connection with a global offering - GlobeNewsWire
- 6 years ago - Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe - GlobeNewsWire
- 6 years ago - Orphazyme A/S provides update on previously announced global offering - GlobeNewsWire
- 6 years ago - Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C - GlobeNewsWire
- 6 years ago - Denmark's Orphazyme files to go public on Nasdaq - Market Watch